Results 11 to 20 of about 174,356 (352)

Mutations of the BRAF gene in human cancer [PDF]

Nature, 2002
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis ...
Jon Teague, Kristian Gray, Jamie Hughes
exaly   +3 more sources

Mechanisms of Reactivation and Its Interaction with [PDF]

Endocrinology and Metabolism, 2020
The telomerase reverse transcriptase (TERT) gene, which is repressed in most differentiated human cells, can be reactivated by somatic TERT alterations and epigenetic modulations.
Young Shin Song, Young Joo Park
doaj   +1 more source

A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC [PDF]

, 2015
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor mediating the toxicity and tumor-promoting properties of dioxin. AHR has been reported to be overexpressed and constitutively active in a variety of solid tumors, but few data
Barollo, Susi, Bertazza, Loris, Bisognin, Andrea, Bortoluzzi, Stefania, Boscaro, Marco, Ceccato, Filippo, Ciato, Denis, Galuppini, Francesca, Guzzardo, Vincenza, Jaffrain Rea, Marie Lise, Mian, Caterina, Occhi, Gianluca, Pennelli, Gianmaria, Regazzo, Daniela, Scaroni, Carla, Vianello, Federica, WATUTANTRIGE FERNANDO, Sara   +16 more
core   +16 more sources

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer

Archives of Medical Science, 2021
Introduction Detection of abnormalities in the KRAS, NRAS and BRAF genes is extremely important for proper qualification of colorectal cancer (CRC) patients for therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies.
Aleksandra Bożyk, Paweł Krawczyk, Katarzyna Reszka, Kinga Krukowska, Agnieszka Kolak, Sławomir Mańdziuk, Kamila Wojas-Krawczyk, Rodryg Ramlau, Janusz Milanowski   +8 more
doaj   +1 more source

CRAF R391W is a melanoma driver oncogene. [PDF]

, 2016
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad, Avramis, Earl, Chmielowski, Bartosz, Friedman, Michael, Graeber, Thomas G, Lassen, Amanda, Le, Allison, Lomova, Anastasia, Ng, Charles, Ribas, Antoni, Titz, Bjoern, Tsoi, Jennifer   +11 more
core   +7 more sources

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

Efficacy and Mechanism Evaluation, 2022
Background: Complex trials with innovative designs are becoming increasingly common and offer the potential to improve patient outcomes in a shorter time frame.
Louise C Brown, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Susan D Richman, Philip Quirke, Rachel Butler, Helen Roberts, Janet Graham, Richard H Wilson, Timothy S Maughan   +12 more
doaj   +1 more source

Clinicopathological relevance of BRAF and SMO mutations in Chinese patients with ameloblastoma

All Life, 2023
Ameloblastomas are benign tumors associated with recurrence and morbidity. Mutations in the V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and smoothened (SMO) genes have been identified in ameloblastomas.
Chen Ruixue, Li Hexiang, Hou Yali, Li Xiangjun, Sun Xu, Wang Jie, Zhang Xudong   +6 more
doaj   +1 more source

Mutation profile of the tall cell variant of papillary thyroid carcinoma: analysis of 5 cases using wide-panel next-generation sequencing

Опухоли головы и шеи, 2021
The study objective is to analyze the mutation profile of the tall cell variant (TCV) of papillary thyroid carcinoma (PTC).Materials and methods. The main inclusion criteria according to the WHO classification (2017) was PTC composed of at least 30 % of ...
I. L. Plaksa, M. R. Savchuk, N. V. Shved, N. A. Savelov, D. N. Khmelkova, А. A. Isaev, R. V. Deev   +6 more
doaj   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas [PDF]

, 2018
Pilocytic astrocytomas represent the most common glioma subtype in young patients and account for 5.4% of all gliomas. They are characterized by alterations in the RAS–MAP kinase pathway, the most frequent being a tandem duplication on chromosome 7q34 ...
Appay, Romain, Badiali, Manuela, Barets, Doriane, Colin, Carole, Figarella-Branger, Dominique, Fina, Frédéric, Giangaspero, Felice, Korshunov, Andrey, M. Pfister, Stefan, Macagno, Nicolas, Ordioni, Joanna, Padovani, Laëtitia, Scavarda, Didier, T. W. Jones, David   +13 more
core   +3 more sources